LeserbriefKommentar
Bleeding in Patients With Atrial Fibrillation—Reply
JAMA · 2024
DOI: 10.1001/jama.2024.13792 ↗Kurz gefasst
Leserbrief in der Zeitschrift JAMA, 2024. Verfasst von Wayne A Ray und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee. Hauptthemen laut MEDLINE: Anticoagulants, Atrial Fibrillation, Hemorrhage. Die Arbeit nennt 2 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
AnticoagulantsAtrial FibrillationHemorrhageHumansStrokeSex FactorsMaleFemaleAdministration, OralDiltiazemDrug InteractionsRivaroxaban
Substanzen
AnticoagulantsDiltiazemRivaroxaban
Autor:innen und Institutionen
- Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee.
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.
Zitieren
APA
Ray, W. A., Stein, C. M., & Murray, K. T. (2024). Bleeding in Patients With Atrial Fibrillation—Reply. JAMA. https://doi.org/10.1001/jama.2024.13792
Vancouver
Ray WA, Stein CM, Murray KT. Bleeding in Patients With Atrial Fibrillation—Reply. JAMA. 2024. doi:10.1001/jama.2024.13792
BibTeX
@article{Ray2024,
author = {Ray, Wayne A and Stein, C Michael and Murray, Katherine T},
title = {Bleeding in Patients With Atrial Fibrillation—Reply},
journal = {JAMA},
year = {2024},
doi = {10.1001/jama.2024.13792}
}
EUVIMED